Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 1999

View Archived Issues

Naloxone's capacity to prevent adverse cognitive effects of ECT assessed

Activity of a glycopeptide antibiotic assessed in vitro and in vivo

Liposomal clofazimine assessed in murine tuberculosis

Hair growth promoters developed at Shiseido

Phase II trial expanded for Aronex's renal cell carcinoma product

Pfizer prepares new class of MMP inhibitors with hydroxamic acid structure

Preparation and use of P2T receptor antagonists in AstraZeneca's portfolio

Selective glucocorticoid receptor modulators emerge from Abbott-Ligand collaboration

Protease-inhibitory cephams and cephems and their use patented by Pliva

Synsorb Biotech searches for treatments for bacterial toxin-induced diseases

VUF-K-8788: new antiallergic agent characterized in experimental studies

Selective muscarinic M4 receptor blockade as potential new treatment option for PD

LifeTime and Arkios enter oncology alliance

Merck & Co. launches preservative-free HBV vaccine

Celgene reports initial results for phase II ADD/ADHD Rx trials

Oxagen broadens collaboration in IBD research

Korean researchers investigate novel 1beta-methylcarbapenems

Hollis-Eden updates progress of HE-2000 clinical trials

New acylquinoline selected for development as antiulcer agent by Korean investigators

Medinox's NOX-100 demonstrates potential as treatment of hemorrhagic shock

LEX-032, a recombinant serpin with beneficial effects on ischemia/reperfusion-induced pancreatitis

Synaptic and Merck & Co. discontinue development of oral treatment for BPH

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...